Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Alebund Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Alebund Pharmaceuticals Raises $60 million in Series B Financing Round

Details:

Alebund Pharmaceuticals lead product, AP-301, is a best-in-class potential in the treatment of hyperphosphatemia.

Lead Product(s): Solnatide

Therapeutic Area: Nephrology Product Name: AP-301

Highest Development Status: Phase II Product Type: Undisclosed

Partner/Sponsor/Collaborator: Quan Capital

Deal Size: $60.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing May 09, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY